Terns Pharmaceuticals, Inc.

NasdaqGS:TERN Stock Report

Market Cap: US$4.1b

Terns Pharmaceuticals Valuation

Is TERN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of TERN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate TERN's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate TERN's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TERN?

Key metric: As TERN is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for TERN. This is calculated by dividing TERN's market cap by their current book value.
What is TERN's PB Ratio?
PB Ratio14.5x
BookUS$284.07m
Market CapUS$4.11b

Price to Book Ratio vs Peers

How does TERN's PB Ratio compare to its peers?

The above table shows the PB ratio for TERN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average3.1x
AVIR Atea Pharmaceuticals
1x5.36%US$324.2m
CRNX Crinetics Pharmaceuticals
4.3x48.49%US$4.6b
CTNM Contineum Therapeutics
3xn/aUS$547.9m
LGND Ligand Pharmaceuticals
3.9x22.53%US$3.7b
TERN Terns Pharmaceuticals
14.5x-2.83%US$4.1b

Price-To-Book vs Peers: TERN is expensive based on its Price-To-Book Ratio (14.5x) compared to the peer average (3.1x).

Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Book Ratio vs Industry

How does TERN's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

23 CompaniesPrice / BookEstimated GrowthMarket Cap
PLRX Pliant Therapeutics
0.3x0.21%US$70.05m
CTXR Citius Pharmaceuticals
0.2x47.75%US$15.67m
KPRX Kiora Pharmaceuticals
0.4x61.14%US$7.89m
INM InMed Pharmaceuticals
0.3xn/aUS$3.72m
TERN 14.5xIndustry Avg. 2.4xNo. of Companies23PB01.63.24.86.48+
23 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: TERN is expensive based on its Price-To-Book Ratio (14.5x) compared to the US Pharmaceuticals industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is TERN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TERN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio14.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate TERN's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TERN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$37.77
US$58.13
+53.89%
8.36%US$70.00US$54.00n/a8
Feb ’27US$34.60
US$58.13
+67.99%
8.36%US$70.00US$54.00n/a8
Jan ’27US$40.40
US$53.56
+32.56%
25.60%US$70.00US$17.00n/a9
Dec ’26US$27.53
US$30.44
+10.59%
22.34%US$36.00US$17.00n/a9
Nov ’26US$8.26
US$15.83
+91.61%
35.87%US$28.00US$7.44n/a9
Oct ’26US$7.81
US$17.81
+127.98%
40.22%US$34.00US$7.44n/a8
Sep ’26US$6.96
US$20.00
+187.36%
33.29%US$34.00US$14.00n/a6
Aug ’26US$5.47
US$20.00
+265.63%
33.29%US$34.00US$14.00n/a6
Jul ’26US$3.85
US$19.14
+397.22%
34.02%US$34.00US$14.00n/a7
Jun ’26US$3.11
US$19.14
+515.53%
34.02%US$34.00US$14.00n/a7
May ’26US$3.56
US$19.06
+435.46%
40.22%US$34.00US$7.50n/a8
Apr ’26US$2.56
US$19.06
+644.63%
40.22%US$34.00US$7.50n/a8
Mar ’26US$3.69
US$19.06
+416.60%
40.22%US$34.00US$7.50n/a8
Feb ’26US$4.46
US$19.06
+327.41%
40.22%US$34.00US$7.50US$34.608
Jan ’26US$5.54
US$19.06
+244.09%
40.22%US$34.00US$7.50US$40.408
Dec ’25US$6.24
US$18.19
+191.47%
37.09%US$30.00US$7.50US$27.538
Nov ’25US$6.94
US$17.94
+158.47%
39.92%US$30.00US$5.50US$8.268
Oct ’25US$8.10
US$18.07
+123.10%
42.31%US$30.00US$5.50US$7.817
Sep ’25US$7.62
US$14.21
+86.54%
38.53%US$22.00US$5.50US$6.967
Aug ’25US$7.77
US$14.21
+82.94%
38.53%US$22.00US$5.50US$5.477
Jul ’25US$6.85
US$14.21
+107.51%
38.53%US$22.00US$5.50US$3.857
Jun ’25US$6.01
US$14.21
+136.51%
38.53%US$22.00US$5.50US$3.117
May ’25US$5.08
US$14.21
+179.81%
38.53%US$22.00US$5.50US$3.567
Apr ’25US$7.10
US$14.21
+100.20%
38.53%US$22.00US$5.50US$2.567
Mar ’25US$7.31
US$14.50
+98.36%
38.35%US$22.00US$5.50US$3.697
Feb ’25US$5.26
US$14.50
+175.67%
38.35%US$22.00US$5.50US$4.467
US$58.13
Fair Value
35.0% undervalued intrinsic discount
8
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/09 14:11
End of Day Share Price 2026/02/06 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Terns Pharmaceuticals, Inc. is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBarclays
Etzer DaroutBMO Capital Markets Equity Research
Evan SeigermanBMO Capital Markets Equity Research